SYNAGIS® (palivizumab) CODING RESOURCE

Access 360™ provides coding and coverage support at 1-877-778-9010. This guide contains potential codes to consider related to products supported by Access 360.

This guide is for informational purposes only and is not intended as coverage or coding advice. MedImmune cannot provide specific reimbursement rates, and does not guarantee reimbursement. You should verify the appropriate reimbursement information for services or items you provide. Contact the insurer to determine your patient’s current benefits and limitations.

National Drug Code (NDC)
The National Drug Code (NDC) is a universal, unique, 3-segment number identifying drugs by manufacturer, dosage, and package size. The Health Insurance Portability and Accountability Act (HIPAA) format for electronic claim submission requires an 11-digit format for NDC codes. Electronic claims may be denied for drugs billed without a valid 11-digit NDC.

Contact your patient’s health plan to determine claim submission requirements and to determine accurate reporting of NDC codes.

<table>
<thead>
<tr>
<th>Dosage</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 mg vial</td>
<td>60574-4114-01</td>
</tr>
<tr>
<td>100 mg vial</td>
<td>60574-4113-01</td>
</tr>
</tbody>
</table>

11-digit NDC (for electronic claims)

<table>
<thead>
<tr>
<th>Dosage</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 mg vial</td>
<td>60574-4114-01</td>
</tr>
<tr>
<td>100 mg vial</td>
<td>60574-4113-01</td>
</tr>
</tbody>
</table>

Submitting accurate codes and claims is important to ensure proper reimbursement of services. The chart below lists potential Common Procedural Terminology (CPT) codes for your reference when submitting claims for your Synagis patients.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>90378</td>
<td>Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each</td>
</tr>
<tr>
<td>96372</td>
<td>Therapeutic, prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular</td>
</tr>
</tbody>
</table>

Healthcare Common Procedure Coding System (HCPCS)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S9562</td>
<td>Home injectable therapy, palivizumab, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem</td>
</tr>
</tbody>
</table>

Select Safety Information
Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

Please see Important Safety Information on page 5.
Synagis

When filing claims for Synagis, providers often indicate a diagnosis code reflecting the patient’s condition. Some examples of diagnosis codes that may be appropriate for the care of RSV prophylaxis candidates are listed below. It is important to note that the codes identified below are examples only. Each provider is responsible for ensuring all coding is accurate. The use of the following codes does not guarantee reimbursement.

International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification = ICD-9-CM/ICD-10-CM

**Diagnosis Codes**

<table>
<thead>
<tr>
<th>ICD-9-CM</th>
<th>Description</th>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>765.00</td>
<td>Extreme immaturity, unspecified [weight]</td>
<td>P07.00*</td>
<td>Extremely low birth weight newborn, unspecified weight</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07.10*</td>
<td>Other low birth weight newborn, unspecified weight</td>
</tr>
<tr>
<td>765.10</td>
<td>Other preterm infants, unspecified [weight]</td>
<td>P07.00*</td>
<td>Extremely low birth weight newborn, unspecified weight</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07.10*</td>
<td>Other low birth weight newborn, unspecified weight</td>
</tr>
<tr>
<td>765.20</td>
<td>Unspecified weeks of gestation</td>
<td>P07.20</td>
<td>Extreme immaturity of newborn, unspecified weeks of gestation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07.30</td>
<td>Preterm newborn, unspecified weeks of gestation</td>
</tr>
<tr>
<td>765.21</td>
<td>Less than 24 completed weeks of gestation</td>
<td>P07.21</td>
<td>Extreme immaturity of newborn, gestational age less than 23 completed weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07.22</td>
<td>Extreme immaturity of newborn, gestational age 23 completed weeks</td>
</tr>
<tr>
<td>765.22</td>
<td>24 completed weeks of gestation</td>
<td>P07.23</td>
<td>Extreme immaturity of newborn, gestational age 24 completed weeks</td>
</tr>
<tr>
<td>765.23</td>
<td>25-26 completed weeks of gestation</td>
<td>P07.24</td>
<td>Extreme immaturity of newborn, gestational age 25 completed weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07.25</td>
<td>Extreme immaturity of newborn, gestational age 26 completed weeks</td>
</tr>
<tr>
<td>765.24</td>
<td>27-28 completed weeks of gestation</td>
<td>P07.26</td>
<td>Extreme immaturity of newborn, gestational age 27 completed weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07.31</td>
<td>Preterm newborn, gestational age 28 completed weeks</td>
</tr>
<tr>
<td>765.25</td>
<td>29-30 completed weeks of gestation</td>
<td>P07.32</td>
<td>Preterm newborn, gestational age 29 completed weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07.33</td>
<td>Preterm newborn, gestational age 30 completed weeks</td>
</tr>
<tr>
<td>765.26</td>
<td>31-32 completed weeks of gestation</td>
<td>P07.34</td>
<td>Preterm newborn, gestational age 31 completed weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07.35</td>
<td>Preterm newborn, gestational age 32 completed weeks</td>
</tr>
</tbody>
</table>

### Diagnosis Codes (Continued)

<table>
<thead>
<tr>
<th>ICD-9-CM</th>
<th>Description</th>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>765.27</td>
<td>33-34 completed weeks of gestation</td>
<td>P07.36</td>
<td>Preterm newborn, gestational age 33 completed weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P07.37</td>
<td>Preterm newborn, gestational age 34 completed weeks</td>
</tr>
<tr>
<td>765.28</td>
<td>35 completed weeks of gestation</td>
<td>P07.38</td>
<td>Preterm newborn, gestational age 35 completed weeks</td>
</tr>
</tbody>
</table>

#### Bronchopulmonary Dysplasia/ Chronic Lung Disease of Prematurity

<table>
<thead>
<tr>
<th>ICD-9-CM</th>
<th>Description</th>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>770.7</td>
<td>Chronic respiratory disease arising in the perinatal period</td>
<td>P27.1</td>
<td>Bronchopulmonary dysplasia originating in the perinatal period</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P27.8</td>
<td>Other chronic respiratory diseases originating in the perinatal period</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P27.9</td>
<td>Unspecified chronic respiratory disease originating in the perinatal period</td>
</tr>
</tbody>
</table>

#### Hemodynamically Significant Congenital Heart Disease

<table>
<thead>
<tr>
<th>ICD-9-CM</th>
<th>Description</th>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>425.4</td>
<td>Other primary cardiomyopathies</td>
<td>I42.9</td>
<td>Cardiomyopathy, unspecified</td>
</tr>
<tr>
<td>428.0</td>
<td>Congestive heart failure, unspecified</td>
<td>I50.9</td>
<td>Heart failure, unspecified</td>
</tr>
<tr>
<td>745.0</td>
<td>Common truncus</td>
<td>Q20.0</td>
<td>Common arterial trunk</td>
</tr>
<tr>
<td>745.1</td>
<td>Transposition of great vessels</td>
<td>Q20.3</td>
<td>Discordant ventriculoarterial connection</td>
</tr>
<tr>
<td>745.11</td>
<td>Double outlet right ventricle</td>
<td>Q20.1</td>
<td>Double outlet right ventricle</td>
</tr>
<tr>
<td>745.2</td>
<td>Tetralogy of Fallot</td>
<td>Q21.3</td>
<td>Tetralogy of Fallot</td>
</tr>
<tr>
<td>745.4</td>
<td>Ventricular septal defect</td>
<td>Q21.0</td>
<td>Ventricular septal defect</td>
</tr>
<tr>
<td>745.5</td>
<td>Ostium secundum type atrial septal defect</td>
<td>Q21.1</td>
<td>Atrial septal defect</td>
</tr>
<tr>
<td>745.6</td>
<td>Endocardial cushion defect</td>
<td>Q21.2</td>
<td>Atrioventricular septal defect</td>
</tr>
<tr>
<td>745.9</td>
<td>Unspecified defect of septal closure</td>
<td>Q21.9</td>
<td>Congenital malformation of cardiac septum, unspecified</td>
</tr>
<tr>
<td>746.0</td>
<td>Congenital anomalies of pulmonary valve</td>
<td>Q22.3</td>
<td>Other congenital malformations of pulmonary valve</td>
</tr>
</tbody>
</table>
This list represents many of the diagnoses of patients with hemodynamically significant CHD who were enrolled in the pivotal CHD clinical trial involving Synagis (palivizumab). Other diagnoses and codes associated with hemodynamically significant CHD may also be considered.

<table>
<thead>
<tr>
<th>ICD-9-CM</th>
<th>Description</th>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>746.1</td>
<td>Tricuspid atresia and stenosis, congenital</td>
<td>022.4</td>
<td>Congenital tricuspid stenosis</td>
</tr>
<tr>
<td>746.2</td>
<td>Ebstein's anomaly</td>
<td>022.5</td>
<td>Ebstein's anomaly</td>
</tr>
<tr>
<td>746.3</td>
<td>Congenital stenosis of aortic valve</td>
<td>023.0</td>
<td>Congenital stenosis of aortic valve</td>
</tr>
<tr>
<td>746.4</td>
<td>Congenital insufficiency of aortic valve</td>
<td>023.1</td>
<td>Congenital insufficiency of aortic valve</td>
</tr>
<tr>
<td>746.5</td>
<td>Congenital mitral stenosis</td>
<td>023.2</td>
<td>Congenital mitral stenosis</td>
</tr>
<tr>
<td>746.6</td>
<td>Congenital mitral insufficiency</td>
<td>023.3</td>
<td>Congenital mitral insufficiency</td>
</tr>
<tr>
<td>746.7</td>
<td>Hypoplastic left heart syndrome</td>
<td>023.4</td>
<td>Hypoplastic left heart syndrome</td>
</tr>
<tr>
<td>746.8</td>
<td>Other specified congenital anomalies of heart</td>
<td>024.8</td>
<td>Other specified congenital malformations of heart</td>
</tr>
<tr>
<td>746.85</td>
<td>Coronary artery anomaly</td>
<td>024.5</td>
<td>Malformation of coronary vessels</td>
</tr>
<tr>
<td>746.9</td>
<td>Unspecified congenital anomaly of heart</td>
<td>020.9</td>
<td>Congenital malformation of cardiac chambers and connections, unspecified</td>
</tr>
<tr>
<td></td>
<td></td>
<td>024.9</td>
<td>Congenital malformation of heart, unspecified</td>
</tr>
<tr>
<td>747.0</td>
<td>Patent ductus arteriosus</td>
<td>025.0</td>
<td>Patent ductus arteriosus</td>
</tr>
<tr>
<td>747.1</td>
<td>Coarctation of aorta</td>
<td>025.1</td>
<td>Coarctation of aorta</td>
</tr>
<tr>
<td>747.11</td>
<td>Interruption of aortic arch</td>
<td>025.2</td>
<td>Astresia of aorta</td>
</tr>
<tr>
<td>747.2</td>
<td>Other congenital anomalies of aorta</td>
<td>025.4</td>
<td>Other congenital malformations of aorta</td>
</tr>
<tr>
<td>747.3</td>
<td>Anomalies of pulmonary artery</td>
<td>025.79</td>
<td>Other congenital malformations of pulmonary artery</td>
</tr>
<tr>
<td>747.4</td>
<td>Congenital anomalies of great veins</td>
<td>026.9</td>
<td>Congenital malformation of great vein, unspecified</td>
</tr>
<tr>
<td>747.41</td>
<td>Total anomalous pulmonary venous connection</td>
<td>026.2</td>
<td>Total anomalous pulmonary venous connection</td>
</tr>
<tr>
<td>747.42</td>
<td>Partial anomalous pulmonary venous connection</td>
<td>026.3</td>
<td>Partial anomalous pulmonary venous connection</td>
</tr>
</tbody>
</table>
SYNAGIS® (palivizumab)
IMPORTANT SAFETY INFORMATION

Synagis® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). The recommended dose of Synagis is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.

The efficacy of Synagis at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

Synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to Synagis. Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to Synagis. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to Synagis. The relationship between these reactions and the development of antibodies to Synagis is unknown. If a significant hypersensitivity reaction occurs with Synagis, its use should be permanently discontinued. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration of Synagis. As with any intramuscular injection, Synagis should be given with caution to children with thrombocytopenia or any coagulation disorder. Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

Please see accompanying full Prescribing Information for Synagis, including Patient Information.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS.

SYNAGIS® (palivizumab) injection for intramuscular use
Initial U.S. Approval: 1998

INDICATIONS AND USAGE
Synagis is a respiratory syncytial virus (RSV) F protein inhibitor monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.

- Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD).
- The safety and efficacy of Synagis have not been established for treatment of RSV disease.

DOSEAGE AND ADMINISTRATION
15 mg per kg of body weight, administered intramuscularly prior to commencement of the RSV season and remaining doses administered monthly throughout the RSV season.

Children undergoing cardio-pulmonary bypass should receive an additional dose of Synagis as soon as possible after the cardio-pulmonary bypass procedure (even if sooner than a month from the previous dose). Thereafter, doses should be administered monthly as scheduled. (2.1, 12.3)

DOSE FORMS AND STRENGTHS
Single-dose liquid solution vials: 50 mg per 0.5 mL and 100 mg per 1 mL (3)

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Dosing Information
2.2 Administration Instructions
3 DOSE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hypersensitivity Reactions
5.2 Coagulation Disorders
5.3 RSV Diagnostic Test Interference
5.4 Treatment of RSV Disease
5.5 Proper Administration
6 ADVERSE REACTIONS
6.1 Clinical Studies Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
8 USE IN SPECIFIC POPULATIONS
9 PREGNANCY
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.3 Pharmacokinetics
12.4 Microbiology
13 NONCLINICAL TOXICOLOGY
14 CLINICAL STUDIES
15 HOW SUPPLIED/STORAGE AND HANDLING
16 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

- Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD) [see Clinical Studies (14)].
- The safety and efficacy of Synagis have not been established for treatment of RSV disease.

DOSE AND ADMINISTRATION
The recommended dose of Synagis is 15 mg per kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season. In the northern hemisphere, the RSV season typically commences in November and lasts through April, but it may begin earlier or persist later in certain communities.

Synagis serum levels are decreased after cardio-pulmonary bypass [see Clinical Pharmacology (12.3)]. Children undergoing cardio-pulmonary bypass should receive an additional dose of Synagis as soon as possible after the cardio-pulmonary bypass procedure (even if sooner than a month from the previous dose). Thereafter, doses should be administered monthly as scheduled.

The efficacy of Synagis at doses less than 15 mg per kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

- DO NOT SHAKEx OR VIOLENTLy AGITATE THE VIAL.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use any vials exhibiting particulate matter or discoloration.

WARNSINGS AND PRECAUTIONS

- Anaphylaxis and anaphylactic shock (including fatal cases), and other severe acute hypersensitivity reactions have been reported. Permanently discontinue Synagis and administer appropriate medications if such reactions occur. (5.1)
- As with any intramuscular injection, Synagis should be given with caution to children with thrombocytopenia or any coagulation disorder. (5.2)
- Palivizumab may interfere with immunological-based RSV diagnostic tests such as some antigen detection-based assays. (5.3, 12.4)

ADVERSE REACTIONS

Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact MedImmune at 1-877-633-4411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

Safety and effectiveness in children greater than 24 months of age at the start of dosing have not been established. (6.4)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 3/2014

- Using aseptic techniques, attach a sterile needle to a sterile syringe. Remove the flip top from the Synagis vial and wipe the rubber stopper with a disinfectant (e.g., 70% isopropyl alcohol). Insert the needle into the vial and withdraw into the syringe an appropriate volume of solution. Administer immediately after drawing the dose into the syringe.

- Synagis should be administered in a dose of 15 mg per kg intramuscularly using aseptic technique, preferably in the anterolateral aspect of the thigh. The glutal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve. The dose (volume of injection in mL) per month = patient weight (kg) x 15 mg per kg x 100 mg per mL of Synagis. Injection volumes over 1 mL should be given as a divided dose.

- Synagis is supplied as a single-dose vial and does not contain preservatives. Do not re-enter the vial after withdrawal of drug; discard unused portion. Only administer one dose per vial.

- Use sterile disposable syringes and needles. To prevent the transmission of hepatitis viruses or other infectious agents from one person to another, DO NOT reuse syringes and needles.

DOSE FORMS AND STRENGTHS
Single-dose liquid solution vials: 50 mg per 0.5 mL and 100 mg per 1 mL (3)
The following adverse reactions have been identified during post approval use of Synagis. The rates of anti-palivizumab antibody positive results in these trials were 1.1% and 1.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug use.

Limited information from post-marketing reports suggests that, within a single RSV season, 50,000 per microliter) adverse events after a sixth or greater dose of Synagis are similar in character and frequency. An electrochemical luminescence (ECL) based immunogenicity assay, with a higher sensitivity for detecting antibodies to palivizumab in an enzyme-linked immunosorbent assay (ELISA) and are highly specific.

Data described below reflect exposure to Synagis (n=1639) compared with placebo (n=1143) in children 3 days to 24.1 months of age at high risk of RSV-related hospitalization in two clinical trials. Trial 1 was conducted during a single RSV season and studied a total of 1502 children less than or equal to 24 months of age with BPD or infants with premature birth (less than 32 weeks gestation) who were less than or equal to 6 months of age at study entry. Trial 2 was conducted over four consecutive seasons among a total of 1287 children less than or equal to 24 months of age with hemodynamically significant congenital heart disease.

In Trials 1 and 2 combined, fever and rash were each reported more frequently among Synagis than placebo recipients, 27% versus 25%, and 12% versus 10%, respectively. Adverse reactions observed in the 153-patient crossover study comparing the liquid and lyophilized formulations were comparable for the two formulations, and were similar to those observed with Synagis in Trials 1 and 2.

In Trial 1, the incidence of anti-palivizumab antibody following the fourth injection was 1.1% in the placebo group and 0.7% in the Synagis group. In children receiving Synagis for a second season, one of the fifty-six children had transient, low titer reactivity. This reactivity was not associated with adverse events or alteration in serum concentrations.

The ELISA assay was highly specific for detecting antibodies to palivizumab in an enzyme-linked immunosorbent assay (ELISA) and are highly sensitive on the sensitivity and specificity of the assay. The ELISA has substantial limitations in detecting anti-palivizumab antibodies in the presence of palivizumab. Immunogenicity samples tested with the ELISA assay likely contained palivizumab at levels that may interfere with the detection of anti-palivizumab antibodies.

An electrochemical luminescence (ECL) based immunogenicity assay, with a higher sensitivity for detecting palivizumab presence compared to the ELISA, was used to evaluate the presence of anti-palivizumab antibodies in subject samples from two additional clinical trials. The rates of anti-palivizumab antibody positive results in these trials were 1.1% and 1.5%.

The following adverse reactions have been identified during post approval use of Synagis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug use.

Blood and Lymphatic System Disorders: severe thrombocytopenia (platelet count less than 50,000 per microliter)

General Disorders and Administration Site Conditions: injection site reactions

Limited information from post-marketing reports suggests that, within a single RSV season, adverse events after a sixth or greater dose of Synagis are similar in character and frequency to those after the initial five doses.

No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of children in the placebo and Synagis groups who received routine childhood vaccines, influenza vaccine, bronchodilators, or corticosteroids were similar and no incremental increase in adverse reactions was observed among children receiving these agents.

The safety and efficacy of Synagis in children greater than 24 months of age at the start of dosing have not been established.

OVERDOSAGE

Overdoses with doses up to 85 mg per kg have been reported in clinical studies and post-marketing experience with Synagis, and in some cases, adverse reactions were reported. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.

DESCRIPTION

Palivizumab is a humanized monoclonal antibody (IgG1x1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domain of human IgG1 and the variable framework regions of the V_{H} genes Cor and Cess. The human light chain sequence was derived from the constant domain of Ck and the variable framework regions of the V_{L} gene K104 with J_{k}X. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy chains and two light chains and has a molecular weight of approximately 148,000 Daltons.

Synagis is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. Thimerosal or other mercury-containing salts are not used in the production of Synagis. The solution has a pH of 6.0 and should appear clear or slightly opalescent.

Each 100 mg single-dose vial of Synagis liquid solution contains 100 mg of palivizumab and also contains chloride (0.5 mg), glycine (0.1 mg), and histidine (3.9 mg). In a volume of 1 mL. Each 50 mg single-dose vial of Synagis liquid solution contains 50 mg of palivizumab and also contains chloride (0.2 mg), glycine (0.06 mg), and histidine (1.9 mg), in a volume of 0.5 mL.

CLINICAL PHARMACOLOGY

Mechanism of Action

Palivizumab is a recombinant humanized monoclonal antibody with anti-RSV activity [see Microbiology (12.4)].

Pharmacokinetics

In children less than or equal to 24 months of age without congenital heart disease (CHD), the mean half-life of palivizumab was 20 days and monthly intramuscular doses of 15 mg per kg achieved mean plasma trough serum drug concentrations of 37 ± 21 mcg per mL after the first injection, 57 ± 41 mcg per mL after the second injection, 68 ± 51 mcg per mL after the third injection, and 72 ± 50 mcg per mL after the fourth injection. Trough concentrations following the first and fourth Synagis dose were similar in children with CHD and in non-cardiac patients. In children given Synagis for a second season, the mean ± SD serum palivizumab concentrations following the first and fourth injections were 61 ± 17 mcg per mL and 98 ± 31 mcg per mL, respectively.

In 139 children less than or equal to 24 months of age with hemodynamically significant CHD who received Synagis and underwent cardio-pulmonary bypass for open-heart surgery, the mean ± SD palivizumab serum concentrations was 98 ± 52 mcg per mL before bypass and declined to 41 ± 33 mcg per mL after bypass, a reduction of 58% [see Dosage and Administration (2.1)]. The clinical significance of this reduction is unknown.

Specific studies were not conducted to evaluate the effects of demographic parameters on palivizumab pharmacokinetics. However, no effects of gender, age, body weight, or race on palivizumab serum trough concentrations were observed in a clinical study with 639 children with CHD (less than or equal to 24 months of age) receiving five monthly intramuscular injections of 15 mg per kg of Synagis. The pharmacokinetics and safety of Synagis liquid solution and Synagis lyophilized formulation administered via intramuscular injection at 15 mg per kg were studied in a cross-over trial of 153 infants less than or equal to 6 months of age with a history of CHD. The results of this trial indicated that the trough serum concentrations of palivizumab were comparable between the liquid solution and the lyophilized formulation, which was the formulation used in the clinical studies. A population pharmacokinetic analysis was performed across 22 studies in 1800 patients (1684 pediatric and 116 adult patients) to characterize palivizumab pharmacokinetics and inter-subject variability in serum concentrations. Palivizumab pharmacokinetics was described by a two-compartment linear model with an elimination half-life of 24.5 days in pediatric patients. Clearance of palivizumab in a clinical pediatric patient (body weight 4.5 kg) was estimated or equal to 24 months of age without CHD was estimated to be 11 mL per day with a bioavailability of 70% following intramuscular administration. The inter-patient variability in drug clearance was 48.7% (CV%). Covariate analysis did not identify any factors that could account for the inter-patient variability in order to predict serum concentrations a priori in an individual patient.

Mechanism of Action

Palivizumab, a recombinant humanized monoclonal antibody which provides passive immunity against RSV, acts by binding the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process. Palivizumab also prevents cell-to-cell fusion of RSV-infected cells.
of neutralization by palivizumab. Interference of RSV diagnostic assays by palivizumab monoclonal antibodies targeting RSV F protein may be inhibited. Therefore, caution should be used in interpreting negative immunological assay results when clinical observations are consistent with RSV infection. A reverse transcriptase-polymerase chain reaction (RT-PCR) assay, which is not inhibited by palivizumab, may prove useful for laboratory confirmation of RSV infection [see Warnings and Precautions (5.3)].

### 13 NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis, mutagenesis, and reproductive toxicity studies have not been performed.

### 14 CLINICAL STUDIES

The safety and efficacy of Synagis were assessed in two randomized, double-blind, placebo-controlled trials of prophylaxis against RSV infection in children at high risk of an RSV-related hospitalization. Trial 1 was conducted during a single RSV season and studied a total of 1502 children less than or equal to 24 months of age with BPD or infants with prematurity birth (less than or equal to 35 weeks gestation) who were less than or equal to 6 months of age at study entry. Trial 2 was conducted over four consecutive seasons among a total of 1287 children less than or equal to 24 months of age with hemodynamically significant congenital heart disease. In both trials participants received 15 mg per kg Synagis or an equivalent volume of placebo via intramuscular injection monthly for five injections and were followed for 150 days from randomization. In Trial 1, 99% of all subjects completed the study and 93% completed all five injections. In Trial 2, 96% of all subjects completed the study and 92% completed all five injections. The incidence of RSV hospitalization is shown in Table 1. The results were shown to be statistically significant using Fisher's exact test.

#### Table 1: Incidence of RSV Hospitalization by Treatment Group

<table>
<thead>
<tr>
<th>Trial</th>
<th>Impact-RSV</th>
<th>Placebo</th>
<th>Synagis</th>
<th>Difference Between Groups</th>
<th>Relative Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial 1</td>
<td>N</td>
<td>500</td>
<td>1002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalization</td>
<td>53 (10.6%)</td>
<td>48 (4.8%)</td>
<td>5.8%</td>
<td>55%</td>
<td></td>
</tr>
<tr>
<td>Trial 2</td>
<td>N</td>
<td>648</td>
<td>639</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalization</td>
<td>63 (9.7%)</td>
<td>34 (5.3%)</td>
<td>4.4%</td>
<td>45%</td>
<td></td>
</tr>
</tbody>
</table>

In Trial 1, the reduction of RSV hospitalization was observed both in children with BPD (OR 34/266 [12.8%] placebo versus 39/496 [7.9%] Synagis) and in premature infants without BPD (19/234 [8.1%] placebo versus 9/506 [1.8%] Synagis). In Trial 2, reductions were observed in acyanotic (36/305 [11.8%] placebo versus 15/300 [5.0%] Synagis) and cyanotic children (27/243 [7.9%] placebo versus 19/338 [5.6%] Synagis).

The clinical studies do not suggest that RSV infection was less severe among children hospitalized with RSV infection who received Synagis for prophylaxis compared to those who received placebo.

#### 16 HOW SUPPLIED/STORAGE AND HANDLING

Synagis is supplied in single-dose vials as a preservative-free, sterile liquid solution at 100 mg per mL for intramuscular injection.

50 mg vial NDC 60574-4114-1

The 50 mg vial contains 50 mg Synagis in 0.5 mL.

100 mg vial NDC 60574-4113-1

The 100 mg vial contains 100 mg Synagis in 1 mL.

The rubber stopper used for sealing vials of Synagis is not made with natural rubber latex.

### 17 PATIENT COUNSELING INFORMATION

- **Adviser the patient to read the FDA-approved patient labeling (Patient Information)**

The healthcare provider should discuss the potential benefits and risks of Synagis with the parents or guardians of Synagis recipients. Parents or guardians should be informed of the possible side effects of Synagis and of the signs and symptoms of potential allergic reactions and should be advised of the appropriate actions. Parents or guardians should understand the dosing schedule and the importance of compliance with the full course of therapy.

Synagis® is a registered trademark of MedImmune, LLC.

Manufactured by:
MedImmune, LLC
Gaithersburg, MD 20878

U.S. License No. 1799
1-877-633-4411

RAL-SYNV17
Component No.: 26920A
Read this Patient Information before your child starts receiving SYNAGIS and before each injection. The information may have changed. This leaflet does not take the place of talking with your child’s healthcare provider about your child’s condition or treatment.

What is SYNAGIS?
SYNAGIS is a prescription medication that is used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV). Your child is prescribed SYNAGIS because he or she is at high risk for severe lung disease from RSV.

SYNAGIS contains man-made, disease-fighting proteins called antibodies. These antibodies help prevent RSV disease. Children at high risk for severe RSV disease often do not have enough of their own antibodies. SYNAGIS is used in certain groups of children to help prevent severe RSV disease by increasing protective RSV antibodies.

SYNAGIS is not used to treat the symptoms of RSV disease once a child already has it. It is only used to prevent RSV disease.

SYNAGIS is not for adults or for children older than 24 months of age at the start of dosing.

Who should not receive SYNAGIS?
Your child should not receive SYNAGIS if they have ever had a severe allergic reaction to it. Signs and symptoms of a severe allergic reaction could include:

- severe rash, hives, or itching skin
- swelling of the lips, tongue, or face
- closing of the throat, difficulty swallowing
- difficult, rapid, or irregular breathing
- bluish color of skin, lips, or under fingernails
- muscle weakness or foppiness
- a drop in blood pressure
- unresponsiveness

What should I tell my child’s healthcare provider before my child receives SYNAGIS?
Tell your child’s healthcare provider about:
- any reactions you believe your child has ever had to SYNAGIS.
- any bleeding or bruising problems. SYNAGIS is given by injection. If your child has a problem with bleeding or bruises easily, an injection could cause a problem.
- any other medical problems.

Tell your child’s healthcare provider about all the medicines your child takes, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your child’s healthcare provider if your child takes a blood thinner medicine.

How is SYNAGIS given?
- SYNAGIS is given as a monthly injection, usually in the thigh (leg) muscle, by your child’s healthcare provider. Your child’s healthcare provider will prescribe the amount of SYNAGIS that is right for your child (based on their weight).
- Your child’s healthcare provider will give you detailed instructions on when SYNAGIS will be given.
- “RSV season” is a term used to describe the time of year when RSV infections most commonly occur (usually fall through spring in most parts of the country). During this time, RSV is most active, your child will need to receive SYNAGIS shots. Your child’s healthcare provider can tell you when the RSV season starts in your area.
- Your child should receive their first SYNAGIS shot before the RSV season starts to help protect them before RSV becomes active. If the season has already started, your child should receive their first SYNAGIS shot as soon as possible to help protect them when exposure to the virus is more likely.

- SYNAGIS is needed every 28-30 days during the RSV season. Each dose of SYNAGIS helps protect your child from severe RSV disease for about a month. Keep all appointments with your child’s healthcare provider.

- If your child misses an injection, talk to your healthcare provider and schedule another injection as soon as possible.
- Your child may still get severe RSV disease after receiving SYNAGIS; talk to your child’s healthcare provider about what symptoms to look for. If your child has an RSV infection, they should continue to get their scheduled SYNAGIS injections to help prevent severe disease from new RSV infections.
- If your child has certain types of heart disease and has corrective surgery, your healthcare provider may need to give your child an additional SYNAGIS injection soon after surgery.

What are the possible side effects of SYNAGIS?

Side effects may cause serious side effects including:

- Severe allergic reactions (may occur after any dose of SYNAGIS). Such reactions may be life-threatening or cause death.
- See “Who should not take SYNAGIS?” for a list of signs and symptoms.
- Unusual bruising or groups of tiny red spots on the skin.

Call your child’s healthcare provider or get medical help right away if your child has any of the serious side effects listed above after any dose of SYNAGIS.

Common side effects of SYNAGIS include:

- fever
- rash

Other possible side effects include skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort). These are not all the possible side effects of SYNAGIS. Tell your child’s healthcare provider about any side effect that bothers your child or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to MedImmune at 1-877-633-4411.

General Information about SYNAGIS
Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. This leaflet summarizes important information about SYNAGIS. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about SYNAGIS that is written for health professionals.

For more information, go to www.synagis.com or call 1-877-633-4411.

What are the ingredients in SYNAGIS?
Active Ingredient: palivizumab
Inactive Ingredients: chloride, glycine, and histidine

What is RSV?
Respiratory Syncytial Virus (RSV) is a common virus that is easily spread from person to person. RSV infects nearly all children by their second birthday. In most children, RSV infection is usually no worse than a bad cold. For some children, RSV infection can cause serious lung disease (like pneumonia and bronchiolitis) or breathing problems, and affected children may need to be admitted to the hospital or need emergency care.

Children who are more likely to get severe RSV disease (high-risk children) include babies born prematurely (35 weeks or less) or less) or babies born with certain heart or lung problems.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Synagis® is a registered trademark of MedImmune, LLC.

Manufactured by: MedImmune, LLC
Gaithersburg, MD 20878
Issued March 2014

Component No.: 26920A